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Abstract
The presence of hypoxia in tumors has been related to poor prognosis and low
overall survival. In particular, cyclic hypoxia has been related to higher metastatic
potential. Hence, it is important to study the mechanisms involved in the response
of tumors when these experience cyclic hypoxia. In this work A-07-GFP human
melanoma xenografts with dorsal window chambers were used as a model to study
the effects of exposure to cyclic hypoxia on tumor growth and on the morphology
and function of the tumor vascular networks. First-pass imaging of a fluorescent
tracer was used to study the function of tumor vasculature, and tumor vascular
morphology was assessed by producing vascular masks from high-resolution images.
Vascular morphology was described by quantification of vascular length density,
vascular area fraction, interstitial distance and vessel diameter. The function of the
tumor vasculature was assessed by quantification of the blood supply times (BSTs).
It was found that exposure to cyclic hypoxia resulted in higher vascular densities,
a trend towards higher BST values and decreased growth rate in the tumors. The
results could be associated with enhanced angiogenesis in the tumors that received
the cyclic hypoxia treatment due to overexpression of pro-angiogenic genes regulated
by HIF-1α.
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Chapter 1
Introduction
Tumor tissue is characterized by vascular networks with an abnormal structure
that results in an increased geometrical resistance to blood flow. This enhanced
resistance has consequences for the functionality of the vascular network, such as
a low and heterogeneous blood supply. Hypoxic regions, i.e. poorly oxygenated
areas, arise in tumors from the heterogeneities in blood flow and influence the tumor
aggressiveness due to the activation of cellular mechanisms in order to adapt to the
hostile microenvironment.
Clinical studies have shown that hypoxia is associated with bad prognosis and
poor overall survival [1, 2]. Correlation between hypoxia in tumors and metastasis
has been reported for different tumor lines in experimental studies [3, 4, 5, 6] showing
that hypoxia in tumors results in increased metastasis, although the mechanisms for
this vary from line to line. It has also been found that the effect of radiation therapy
is reduced under hypoxic conditions, and that regions with intermittent hypoxia are
more radio-resistent [5]. Moreover, almost all chemotherapeutic agents are active
against rapidly proliferating cells. However, the rate of proliferation in solid tumors
with hypoxic regions might be slower due to the longer distances to the blood vessels
[7], resulting in sparing of tumor cells in chemotherapy [8].
The aim of this work is to study the effects of hypoxia exposure on tumor vascu-
lar networks. Human melanoma xenografts growing in window chamber preparations
were used as tumor models, and were studied by intravital microscopy techniques.
These methods are excellent for quantification of both, the morphology and the
function of vascular networks.
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Chapter 2
Theory
2.1 Tumor physiology
Solid tumors are conformed by cancer and stromal cells, the extracellular matrix
and the vascular network [9]. Many of the differences between tumor and normal
tissue stem from abnormalities in tumor vessels [10]. Tumor vasculature consists
of the previously existing vessels of the tissue in which the tumor evolves and the
newer microvessels that arise through a process known as angiogenesis, so that the
metabolic demands of neoplastic cells are supplied. Both pre-existing and new ves-
sels develop structural abnormalities which result in functional abnormalities and
changes in the tumor microenvironment.
2.1.1 Angiogenesis
In order to survive, mammalian cells need to be located within the diffusion limit
of oxygen from blood vessels, i.e., within 100 to 200 µm [11] from the closest vessel.
Therefore, for tissue to grow above the oxygen diffusion limit, it is necessary to
recruit new vessels through angiogenesis. Normal angiogenesis occurs during fetal
and post natal development as well as in wound healing, and it is a highly regulated
process which takes place during brief periods and is inhibited afterwards. On
the other hand, pathological angiogenesis is an unregulated and persistent process,
characteristic of tumors and some other diseases, such as arthritis, diabetes and
ocular neovascularization [12].
Likewise, tumor growth is dependent on the stimulation of angiogenesis (Fig.
2.1) achieved by disrupting the balance between pro- and anti-angiogenic factors.
This is commonly known as the angiogenic switch.
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Figure 2.1: Angiogenesis is stimulated by the secretion of angiogenic factors from tumor cells
which is a determining step in the survival, growth and spread of a tumor. Figure taken from
reference [13].
The angiogenic switch
On a molecular level, angiogenesis is regulated by the balance of angiogenic acti-
vators and inhibitors. This balance, illustrated in Figure 2.2, determines whether an
endothelial cell remains quiescent or angiogenic, thereby controlling the angiogenic
switch [11, 12, 14, 15]. In solid tumors, the angiogenic switch generally activates
at early stages, often at pre-neoplastic stages [15]. However, the time at which this
step occur varies from one tumor to another [14].
Figure 2.2: The angiogenic switch is on when the balance between pro-angiogenic and anti-
angiogenic factors is disturbed towards the activators of this process.
Among the possible causes for activation of angiogenesis in tumors are: the
metabolic stress to which tumor cells are subjected, e.g., low pH, low O2 and glu-
cose concentration; mechanical stress due to pressure caused by growth of tumor
mass; higher interstitial fluid pressure; inflammatory response and genetic mutations
in tumors. These circumstances will lead to overexpression of angiogenic activa-
tors and/or downregulation of angiogenic inhibitors, thus, triggering the angiogenic
switch [11].
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Angiogenic activators
Experimental studies have revealed a number of angiogenic activators. The first
angiogenic factors found were the basic fibroblast growth factor (bFGF) and acidic
fibroblast growth factor (aFGF). These are proteins that can be released from cells
when the angiogenic phenotype is on, and have a high affinity to heparin. Then,
another protein called vascular endothelial growth factor (VEGF) was discovered as
an inducer of angiogenesis as well as vascular permeability, for which, it was also
called vascular permeability factor (VPF). Both, VEGF and the FGFs proteins bind
to their own receptors: the VEGF receptors (VEGFR-1-3) are located specifically
on endothelial cells, whereas the FGF receptors (FGFR-1-4) are also located in other
kinds of cells [15].
Other important pro-angiogenic molecules are platelet-derived growth factors
(PDGF) and transforming growth factor alpha (TGF-α). TGF-α activates the trans-
formed phenotype in cells and binds to epidermal growth factor (EGF) [12]. This
latter upregulates VEGF and FGF; and lisophosphatic acid (LPA), which also upreg-
ulates the VEGF levels in cells [14]. Hepatocyte growth factor (HGF) and monocyte
chemoattractant protein-1(MCP-1) stimulate the growth of endothelial cells, smooth
muscle cells, fibroblasts and some epithelial cells. Additionally, nitric oxide synthase
(NOS) and cyclo-oxygenase-2 (COX-2) contribute in enhancing vasodilatation [11].
Angiogenic inhibitors
Angiogenic inhibitors exist naturally in cells and participate in the regulation
of the angiogenic process in normal tissue. Some commonly known angiogenic in-
hibitors are thrombospondin-1 and -2 (TSP-1, -2). Thrombospondin is an extra-
cellular matrix molecule that inhibits the proliferation of endothelial cells as well
as their migration, growth and adhesion, and is related to the expression of tumor
suppressor gene p53 [11, 15]. This tumor suppressor gene upregulates the produc-
tion of thrombospondin in cells. Another angiogenic inhibitor is interferon, which
acts by inhibiting migration of capillary endothelial cells [16]. Metalloproteinase
inhibitors (MMPs inhibitors or TIMPs) also have an anti-angiogenetic effects coop-
erating in the degradation of the extracellular matrix [11]. Anti-adhesive peptides
and the synthetic protease inhibitors are fabricated angiogenesis inhibitors. The first
ones act by blocking the interaction of αV β3 and α5β1 integrins, which are angio-
genesis mediators, with the extracellular matrix ligands; and the latter have shown
clinically an anti-tumor and anti-metastatic effect [16]. Angiostatin and endostatin
are tumor-derived inhibitors of angiogenesis. Angiostatin participates in the inhi-
bition of angiogenesis by blocking endothelial migration and proliferation, whereas
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endostatin restrains microvascular endothelial cell proliferation and survival, thereby
complicating tumor growth and metastasis [11, 16].
Anti-angiogenic agents have been studied lately for their applications in can-
cer therapy. The fact that anti-angiogenic therapy could reduce the occurrence of
metastasis and prevent tumor growth, together with the possibility of normalization
of pathologic vascular networks [9] has given rise to a different approach for cancer
therapy.
Sprouting and intussusceptive angiogenesis
The angiogenic process can occur either by sprouting of new vessels or intussus-
ception of existing vessels, as illustrated in Figure 2.3.
Sprouting angiogenesis starts with the dissolution of the basement membrane
of a vessel into the extracellular matrix, then, endothelial cells move towards the
angiogenic stimulus and proliferate leaving a trail along their migration path where
lumen develops and canalization takes place. Subsequently, branches emerge from
the main trail, often conforming loops, and vessels are then covered by pericytes and
a basement membrane forms in them, thereby marking the maturation of the new
branches [17].
Figure 2.3: The angiogenic process can take place as sprouting of new vessel or through intus-
susception of extra cellular matrix columns into the blood vessels.
The other possible angiogenic mechanism is vessel splitting, better known as
intussusception, which occurs by insertion of extracellular matrix columns transcap-
illary pillars. This can happen in vivo if endothelial cells proliferate inside vessels
and thereby a lumen is formed in the vessel and grows dividing it and permitting
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the insertion of transcapillary pillars. Further growth of this columns can lead to
subsequent partitioning of the vascular network [17, 18].
The mechanism by which angiogenesis occur may depend on the type of tissue
or organ where the process takes place due to different abundance or availability of
vessels as well as endothelial cell precursors [18].
2.1.2 Tumor vasculature
The vascular network in tumors differs from that in healthy tissue by presenting
abnormalities in its morphology. These structural abnormalities are responsible for
alterations in the blood flow, i.e., functional abnormalities. In the following subsec-
tion, a review of the morphological abnormalities is presented and its consequences
will be discussed as part of the tumor blood flow section.
Morphological abnormalities of vascular networks in tumors
Structural abnormalities in the vasculature arise from the disturbed balance be-
tween angiogenic inhibitors and activators which leads to a unregulated and, thus
chaotic, development in the vascularity, thereby inducing changes in the morphology,
as shown in Figure 2.4.
Figure 2.4: Normal vasculature (left) and tumor vasculature (right). The tumor vasculature
shows multiple anormalities: A: arteriovenous shunts, B: leakage in vessels, C: capillaries with
blind ends, D: vessel obstructions that can lead to thrombosis and E: hypoxic regions.
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The possible morphological abnormalities in tumor vasculature can be divided
in the following three categories [19], as listed below:
1. Irregularities in the vessel walls: incomplete or missing endothelial lining,
interrupted or absent basement membrane, blood channels lined by tumor cell
cords and lack of contractile wall components.
2. Abnormalities in single vessels: changes in vessel diameter, contour irreg-
ularities, tortuosity and elongation of vessels.
3. Vascular network architectural abnormalities: heterogeneous distribu-
tion of vessels, expansion of inter-capillary space, arteriovenous shunts and loss
of hierarchy.
These irregular architectural features have serious consequences in the blood
flow functionality. This will be discussed in the following section.
2.1.3 Blood flow
The blood flow rate, Q, in either normal or tumor vasculature, is directly propor-
tional to the pressure gradient between the arterial and venous ends of the network
∆p, and inversely proportional to the flow resistance, FR [20], i.e.,
(2.1) Q = ∆p
FR
.
The flow resistance FR of a vascular network, is a complex function dependent
of the morphological parameters of the vascular network (such as number of vessels,
their branching pattern, length, diameter, etc.), and of the rheology of the blood
[20], i.e. it will also depend on the viscosity η of the blood: the more viscous the
blood, the more resistance the vessel will impose to the flow. This means that the
flow resistance FR is a parameter that comprises the geometrical resistance and the
viscous resistance:
(2.2) FR = Zη.
A simplified model to describe the flow resistance in a blood vessel is given by
the Hagen-Poiseuille equation [21] for a laminar flow of blood with viscosity η in a
cylindrical rigid vessel of radius R and length L as,
(2.3) FR = 8ηL
piR4
,
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from where, the geometrical resistance that a vessel exerts on the blood flow Z is
defined as,
(2.4) Z ≡ 8L
piR4
.
Hence, the blood flow rate in terms if the pressure gradient ∆p, the blood viscosity
η and the geometrical resistance Z can be mathematically expressed as [20, 21]:
(2.5) Q = ∆p
ηZ
.
Equation 2.5 shows the impact of the geometry of a vessel on the circulation in
it. This can be extrapolated to elucidate the importance of the geometric resistance
of the vascular network of a tumor as a whole on its functionality. Therefore, the
conjugation of the irregularities in the morphology of tumor vascular networks and
the increased viscous resistance will result in a reduced and less efficient blood flow
inside the tumor.
Functional abnormalities of vascular networks in tumors
Common functional abnormalities observed in tumor vascular networks are inter-
mittent blood flow and variations in its speed and direction, arteriovenous shunt
perfusion, increased vascular fragility, blood extravasation and hemorrhages, ob-
struction of vessels, thrombosis, increased viscous resistance and hemoconcentration
[19].
Altogether, the morphological and functional abnormalities in the vascular
networks of tumors result in an irregular blood flow with temporal and spatial het-
erogeneities. These heterogeneities can lead to certain conditions in the microenvi-
ronment of the tumor such as increased interstitial fluid pressure, decreased pH and
pO2 gradients.
2.1.4 Hypoxia
The reduced blood perfusion in tumors and the higher metabolic rate of neoplastic
cells alter the balance between oxygen supply and demand leading to spatiotemporal
variations of oxygen tension in tumors [22]. Measurements of oxygen tension in nor-
mal subcutaneous tissue obtained with Eppendorf electrodes [23] show that normal
tissue usually have pO2 values ranging from approximately 30 to 70 mmHg, with no
values under 10 mmHg. Yet, the oxygen tension measured in lymph node metastases
of head and neck tumor was much lower, with a median value of approximately 10
mmHg, as presented in Figure 2.5.
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Figure 2.5: Oxygen pressure in a lymph node metastasis of a head and neck tumor and in the
surrounding normal s.c. tissue measured with Eppendorf oxygen electrodes [23, 30]. The median
pO2 value is marked by the hatched bar.
Hypoxia is defined as low oxygen tension in tissue, usually referred to an oxy-
gen tension under a threshold of pO2 < 10 mmHg [24, 25, 26, 27], and can be caused
by transient interruptions of blood vessels, or by limited oxygen diffusion to a cer-
tain region, yet these two mechanisms are not mutually exclusive [22]. Hypoxia is
classified in two subgroups according to its origin, as:
1. Chronic hypoxia. Occurs due to permanent limitations in oxygen diffusion,
typically arising adjacent to necrotic regions, and therefore is also termed
diffusion-limited hypoxia.
2. Acute hypoxia. Due to transient limitations in tumor blood perfusion, block-
age or changes in flux which is why it is also called perfusion-limited hypoxia.
This type of hypoxia can occur cyclicly, and when so, it is termed cyclic hy-
poxia.
Hypoxia has been correlated to limited proliferation and differentiation in tu-
mors, nevertheless, it is well known that hypoxia stimulates adaptability to a hostile
microenvironment thereby increasing tumor aggressiveness [1, 2, 3, 4, 5, 6, 8, 11, 22,
24, 27]. Hence, it is of great importance to understand the pathways underlying the
hypoxic mechanisms in tumors.
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2.1.5 Diffusion-limited hypoxia
Thomlinson and Gray [28, 29] observed two types of cells in histological sections
of bronchial carcinoma: cells that were proliferating normally, and others that were
dying or already dead; and that the main reason of this cell death was the low oxygen
content in the regions where these cells were found, due to the long distances between
them and capillaries.
Figure 2.6: Cross-section of a capillary surrounded by tumor cells illustrating the decrease in
oxygen concentration in the tissue dependent to the distance to the capillary. Normoxic cells
(shown in pink) are close to the capillaries, whereas hypoxic and anoxic cells (shown in grey and
blue, respectively) appear further away from the vessels, to approximately a distance of 70 µm.
Figure from reference [30].
In between the region of the necrotic and normoxic1 cells, tissue with enough
oxygen and nutrients to proliferate but too little oxygen to be radiosensitive was
found. This was denominated hypoxic tissue and was mainly located at approxi-
mately 70 µm from a blood vessel and can therefore be classified as diffusion-limited
or chronic hypoxia.
Diffusion limited hypoxia can also arise from the geometrical resistance in the
vasculature. Figure 2.6 shows a capillary cross section environed by tumor cells which
decrease in oxygen concentration the further they are from the vessel: normoxic
tissue is found closest to the capillary, diffusion-limited or chronic hypoxic tissue is
found between anoxic tissue and the normoxic tissue. The limited diffusion of oxygen
and nutrients in tumors has negative implications for drug delivery in chemotherapy
in addition to ionizing radiation increased resistance, although proliferation far from
the vessels can as well be restricted due to the lack of nutrients.
1At a normal oxygenation status.
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2.1.6 Perfusion-limited hypoxia
Temporary occlusions of vessel inside tumors can be caused by compression of the
microvessels due to fast division of the neoplastic cells or by agglomeration of rela-
tively large white blood cells [31]. In addition, changes in blood flow direction also
result in regions of acute or perfusion-limitted hypoxia. Changes in the oxygenation
status of tumors can occur cyclicly throughout the life span of the cells, moreover,
there has been evidence that some blood vessels in tumors get blocked randomly
for periods of time ranging from around 60 seconds to a couple of hours [32] which
has been the reason why this type of hypoxia has also been denominated cyclic or
intermittent hypoxia.
Figure 2.7: Perfusion-limited hypoxia arises from transient obstructions in the blood flow which
can last from seconds to some hours and may repeat cyclicly, whereas diffusion-limited hypoxia oc-
curs due to cell proliferation outside the oxygen diffusion range from the closest capillary. (Adapted
from reference [29].)
As illustrated in Figure 2.7, acutely hypoxic regions are most likely to ap-
pear close to capillaries. The existence of acute hypoxia has been demonstrated
in a number of experiments. Chaplin et al. injected a short diffusion range flu-
orophore intravenously in mice with murine squamous carcinoma, irradiated the
tumors, dissected them and sorted the tumor cells by their fluorescence intensity
(as an indicator to their proximity to the vessels). Afterwards, the viability of these
cells was assessed using the soft agar clonogenic assay. These researchers found that
there were radioresistant cells in the tumors even adjacently to blood vessels, which
was most likely due to the presence of perfusion limited hypoxia [33]. This same
research group reported that 20-minute-interval sequential injection of fluorescent
markers in mice with the same type of tumors as in the previous experiment resulted
in a mismatch of the staining in the tumors which indicated intermittent perfusion
2.1. TUMOR PHYSIOLOGY 15
due to transient occlusion of vessels during periods of at least 5 minutes [34]. These
mismatch regions appeared randomly distributed throughout the tumors [34].
More recently, occurrence of cyclic hypoxia was demonstrated by measuring
the temporal variations of oxygen tension in human melanoma xenografts with fiber
optic oxygen sensitive probes continuously for one hour [25]. The presence of chronic
and acute hypoxia in this same tumor line was also evidenced by differentiating the
fraction of hypoxic cells with pimonidazole staining (a marker of diffusion limited
hypoxia) from the radioresistant cells, which comprised the chronic and acutely
hypoxic cells in these tumors [6].
The relatively short distance from the blood vessels to acutely hypoxic cells
positions them on a higher energy state than the chronically hypoxic cells, thereby
facilitating intravasation and spread through the circulation. Intermittent hypoxia
in tumors has been related to higher metastatic occurrence, which has been reported
for different tumor lines [3, 4, 5, 6] confirming that for most of the studied tumors,
cyclic hypoxia treatment results in increased metastasis, although the mechanisms
and incidence vary from one tumor line to another. In particular, A-07 melanoma
tumors in vivo exposed to intermittent hypoxic stress present increased angiogenesis,
perfusion and metastatic dissemination [6].
2.1.7 Consequences of hypoxia
Hypoxia induced gene expression
Poorly oxygenated tumor tissue manifest a series of changes as an adaptive re-
sponse in order to survive and proliferate in the hostile microenvironment. Among
the adaptation responses, occurs gene expression for a more effective supply and
utilization of oxygen and nutrients. This gene expression is mostly regulated by the
hypoxia inducible factor 1 (HIF-1) [24, 35, 36, 37, 38].
HIF-1 is an heterodimer consisting of a constitutively expressed nuclear protein
independent of the oxygen tension, the HIF-1β subunit, and one inducible subunit
HIF-1α that is a cytoplasmic protein dependent on oxygen concentration [24, 37, 38].
As shown in Figure 2.8, under normoxic conditions HIF-1α is constantly de-
graded by the ubiquitin-proteasome system, whereas for hypoxic circumstances the
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HIF-1α subunits are translocated to the nucleus. Subsequently, HIF-1α and HIF-1β
dimerize and give rise to a HIF-1 protein that binds to target genes in the DNA,
activating the transcription of the genes expressed under hypoxic conditions [24].
Some of these genes are vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), erythropoietin, inducible nitric oxide synthase (iNOS), epi-
dermal growth factor (EGF), transforming growth factor-beta (TGF-β), insulin-like
growth factor-2 (IGF-2), glycolytic enzymes and glucose transporters [19]. From
these genes, VEGF, PDGF, erythropoietin, EGF and iNOS are pro-angiogenic fac-
tors, this results in hypoxia-driven angiogenesis.
Figure 2.8: Effects of the oxygen level on HIF-1α regulation. In a normoxic environment,
the ubiquitin-proteasome system degrades HIF-1α, whereas in hypoxic conditions HIF-1α hetero-
dimerizes with HIF-1β and binds to elements in the DNA which activate transcriptions and mRNA
synthesis that result in the expression of proteins mediated by hypoxia [24].
Hence, HIF-1 induces an aggressive phenotype in tumors, since a higher vascu-
larization in tumors facilitates metastasis since cancer cells are more likely to enter
the circulation and spread than in tumors with lower vascular densities [24, 39],
and because angiogenesis allows the growth in tumors [11, 12]. Moreover, PDGF,
EGF, IGF-2 and TGF-β are genes that stimulate tumor growth, cell proliferation
and survival. In addition, the glycolytic enzymes and glucose transporters cooperate
in the metabolic adaptation of hypoxic tumors promoting glucose uptake ensuring
that the metabolic requirements are met [24]. These hypoxia-induced mechanisms
are summarized in Figure 2.9.
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Figure 2.9: Causes and consequences of hypoxia and expression of HIF-1α in tumors. Dimer-
ization of HIF-1α in hypoxic cells activates the transcription of genes that favor angiogenesis, cell
proliferation and survival, and metabolic adaptation to the hostile environment, this responses are
related to malignancy in tumors [24].
Effects of hypoxia in cancer treatment
Differences in radiation sensitivity due to the oxygen content in cells were first
quantified by Gray et al. in their study of radiation-induced growth inhibition of a
root of the vicia faba bean [29, 40]. This phenomenon is known as the oxygen effect.
The oxygen effect can be quantified by the calculation of the oxygen enhancement
ratio, OER, defined as the ratio between the doses needed to obtain the same ther-
apeutic effect in hypoxic tissue compared with normoxic tissue [29]. In mammalian
cells, this ratio ranges between 2.5 to 3 for x-ray irradiation [29, 30] which, as shown
in Figure 2.10 (Left), indicates that for a given radiation dose the difference in the
cell surviving fraction can vary in several orders of magnitude. However, the OER
decreases with increasing the density of the ionizing radiation (large for low LET2
radiation such as x-rays, medium for neutrons and insignificant for α-particles [29]).
2LET is the linear energy transfer characterizing a certain radiation defined as the average
energy dE imparted locally in traversing a distance dl [29].
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Figure 2.10: Left: Typical survival curves to ionizing radiation for mammalian cells under
aerobic and hypoxic conditions, the dotted vertical line corresponds to a dose of 14 Gy. Right:
DNA damage caused by ionizing radiation can be restored by interaction with a sulfhydryl group,
or can be made permanent in the presence of oxygen by formation of organic peroxides. Taken
from reference [30].
The absorption of ionizing radiation produces fast charged particles that in-
teract with the biological tissue giving rise to short-life ion pairs which produce free
radicals. These free radicals can break chemical bonds and damage the DNA, cre-
ating a DNA radical that might be chemically restituted if it undergoes reduction
by reacting with a non-protein sulfhydryl (-SH) in the absence of oxygen. Yet, in
the presence of oxygen, organic peroxides are formed, making the damage to DNA
non-restorable [29, 30]. These two pathways are illustrated in Figure 2.10-Right.
Hence, hypoxia is related with less radio-curability in tumors.
Regarding chemotherapy, the effects of hypoxia can be associated to the metabolism
in the hypoxic cancer cells, or to the morphology of vascular network in the tumor.
In the first case, the lack of oxygen, nutrients and reduced glucose in hypoxic cancer
cells can cause an arrest or a slower pace in their course through the cell cycle, which
results in slower proliferation of hypoxic cancer cells [30]. Since, the majority of an-
ticancer drugs are targeting rapidly proliferating cells, slow- and non-proliferating
hypoxic cancer cells might be spared [8]. In the second case, as oxygen has a dif-
fusion limit distance from a vessel, diffusion of the anticancer drugs is limited by
proximity to capillaries. This also implies that the concentration of the drugs will
be higher close to vessels and might be insufficient in regions with chronic hypoxia.
Poorly vascularized and necrotic regions result in a decrease in uptake of therapeutic
agents. This is specially worse for larger tumors where there is a greater necrotic
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volume. Transient blockages of vessels in the tumors will also prevent a sufficient
distribution of anticancer drugs in acutely hypoxic tumor cells. The center of a
tumor is characterized by a high interstitial pressure in comparison to the periphery
leading to low drug uptake and heterogeneous drug distribution. In general, the
geometrical resistance to the blood flow imposed by the vasculature will difficult an
appropriate distribution of chemotherapeutic agents in tumors [30].
Figure 2.11: Kaplan-Meier curves showing the overall survival probability for 89 patients with
cervical tumors. All the patients were treated with curative intent and divided into two groups
according to tumor oxygenation status. Taken from reference [41].
Figure 2.11 shows the of overall for 89 women with cervical tumors with diam-
eters of at least 3 cm. The tumor oxygenation status was measured with Eppendorf
needles and, subsequently, patients were divided in those with normal oxygen ten-
sion tumors (pO2 ≥ 10 mmHg), and those with hypoxic tumors (pO2 ≤ 10 mmHg)
[41]. All patients were treated with curative intent. From these curves, it is evi-
dent that the presence of hypoxia is related to a poor prognosis and overall survival
probability.
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2.2 Tumor model systems
2.2.1 Xenografts
The term xenograft refers to the transplantation of living cells, tissue or organs
from one species to another [29]. Cells from human tumors transplanted to animals,
are often used as model system for cancer in humans. The suitability of xenograft
models varies among different cancer types, for example, melanomas and tumors
from lungs and colon have generally resulted in greater success in xenograft studies
than tumors from breasts and ovaries. Human cancer cells are normally rejected
through immune reactions in animals with a normal immune system. Therefore,
immunodeficient animals are commonly used for cancer research, although the pos-
sibility of rejection of cancer cells is always present.
An example of this is the BALB/c nu/nu mice. This type of mice originated
from spontaneous mutation at the NIH Animal Genetic Resource [42] with lack of
a thymus from birth. Thus, these mice cannot produce T-cells (being therefore im-
munodeficient) which makes them suitable for allografts, xenografts and malignant
tissue research. In addition, these mice are hairless with albino background which
can facilitate intravital microscopy techniques. The lack of thymus and hair in these
mice arises from an autosomal recessive nude gene in homozygous (nu/nu). These
mice are different than the heterozygous (nu/+) which have a normal thymus and
can be haired [43].
A major advantage with xenografts is that the histological features of the
original tumor are mostly preserved [44]. Nevertheless, the supporting tissue and
the vasculature will come from the animal. Human tumor xenografts normally have
a doubling-time of about a fifth of the time observed in humans. This increased
growth rate is an advantage experimentally for practical reasons, but may influence
the results in studies that are sensitive to tumor growth rate [29].
2.2.2 Spheroids
Certain kinds of cells are capable of growing as spheroids. To obtain cellular
growth in spheroid manner, cells must be cultivated to prevent them from attach-
ing to a solid surface [29]. After subsequent individual cell divisions, the cells must
remain attached to each other in order to conform increasingly larger spherical struc-
tures. Cells in the spheroids depend on a passive diffusion of oxygen and nutrients
from the surrounding medium. When the radius of the spheroid is beyond the dif-
fusion limit of oxygen, the center of the spheroid will begin to have a deficiency in
2.3. INTRAVITAL MICROSCOPY 21
oxygen combined with a accumulation of waste which can result in a central necrosis
as growth continues [29]. Spheroids are good in vitro models of a avascular tumors.
Nevertheless, not all tumor cell kinds are able of growing as spheroids.
2.3 Intravital microscopy
Intravital microscopy consists of microscopically imaging intact living tissue. Tis-
sue preparations for intravital microscopy can be either chronic transparent windows,
acute preparations (where the animal in research is prepared surgically to gain direct
access to inner organs), or in situ preparations [46]. Transparent window chambers
implanted in the dorsal skinfold of mice are commonly used models for the study of
tumor vasculature with intravital microscopy. In this case, a tumor grows inside of
one of the skin layers, under a glass window. This glass window makes it possible
to image the vascular network of the tumor. In order to achieve good visualization
of the vasculature, fluorescent contrast agents can be injected intravenously which,
after a short time, distribute throughout the vascular network of the tumor.
2.3.1 Interactions between light and matter
The transit of light through a material leads to exchange processes between the
light and the molecules in the material [47]. These interactions can result in changes
of the direction, polarization and energy of light through different absorption and
energy distribution processes. If the energy of the incoming photons is equal to
or greater than the energy difference between two energy levels in a molecule, the
molecule can absorb the energy and excite to a higher energy level. Both electronic,
vibrational and rotational energy levels can be excited. Since the energy of the
incoming photons is dependent on the wavelength of light, it is possible to use light
with different wavelengths to selectively excite different molecules or different energy
levels in the same molecule. After an excitation takes place, the excited molecule
will expel the absorbed energy and return to the basal state. This de-excitation
can occur through different processes. The most important ones are illustrated
in the Jablonski diagram (Figure 2.12). From these processes, fluorescence and
phosphoresce involve the emission of light. Phosphorescence comprises forbidden
transitions between electronic energy levels with different spin quantum number J .
Fluorescence consists of electronic relaxation without changing the spin quan-
tum numbers for the electrons (∆J = 0), with further emission of a photon with an
energy equal to the excited energy gap. Fluorescence only occurs from the lowest ex-
cited condition to the basal state [48]. In the absence of other relaxation processes,
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Figure 2.12: The Jablonski diagram and spectra of absorption, fluorescence and phosphorescence.
Solid arrows point to radiative transitions through absorption (shown in violet and blue) or emission
of a photon by fluorescence (displayed in green) or phosphorescence (marked in red). Non-radiative
transitions are pointed with dashed arrows. Transition S1,0 →T1,0 (subscripts correspond to the
electronic state and vibrational sublevel, respectively) is termed intersystem crossing since it occurs
between two states of distinct spin multiplicity and is non-radiative. Under the Jablonski diagram,
representations of the absorption, fluorescence and phosphorescence spectra are shown [45].
fluorescence has a life-time of about 10−9 to 10−8 seconds. Other non-radiative
processes compete with fluorescence, among them, internal conversion, dissociation,
chemical reactions and ionization. The emitted fluorescent light has less energy than
the excitation light. The molecule releases the remaining excitation energy through
non light emitting transitions between vibrational levels within the same electronic
energy level. The result is that the fluorescent light gets a shift towards longer wave-
lengths compared to the excitation light. This is called Stokes shift and makes it
possible to separate excitation light from fluorescence light with the help of optical
filters.
2.3.2 Fluorescent markers and contrast agents
The ability of molecules to absorb and emit light with certain frequencies can
be exploited to detect special molecules in a test volume based on the emission
spectrum. Molecules can be naturally fluorescent (a phenomenon called autofluo-
rescence) or can fluoresce due to the presence of other fluorescent molecules.
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Endogenous fluorophores are autofluorescent contrast agents that occur natu-
rally in a sample. Several molecules that occur naturally in cells are auto-fluorescent,
such as NADH, flavins, elastin and collagen [47]. This property can be utilized to
image special structures inside the cell in addition to different cellular processes.
Exogenous fluorophores are fluorescent molecules that can be attached specif-
ically to biological structures. There exist a variety of these fluorophores which
vary in specificity, sensitivity and emission spectra. Some basic requirements for
an exogenous flurophore are solubility, specificity for association with targets, high
quantum emission efficiency, stability and low probability of photobleaching3. When
using different fluorophores simultaneously, it is important that the emission spectra
are sufficiently separated in order to be detected individually.
Green fluorescent protein
Green fluorescent protein (GFP) is a fluorescent protein that occurs naturally in
certain cells of the jellyfish Aequoria Victoria [47]. This protein can be introduced in
cells grown in vitro, or in specific cells in a living organism by means of recombinant
DNA methods: A gene that codes for GFP is introduced in the DNA of the cell,
and results in synthesis of GFP in the cell. These cells are called GFP transfected
cells, and can be detected with fluorescence microscopy by using filter packages that
detect the fluorescence in the green region of the light spectrum.
The unit in GFP that absorbs and emits light is well protected within the
compact folded structure, which reduces the probability of de-excitation through
non-light-emitting processes as a result of interactions with the surroundings. This
makes GFP a robust and stable protein. Several GFP mutant proteins have been
produced. These mutants have higher emission than the original GFP and some
have also different emission spectra [47].
2.3.3 Microscopic imaging techniques
In microscopy the ability of convex lenses to concentrate light is utilized to form
real magnified images of objects that are currently outside the focal plane of the lens.
This simple principle forms the basis of a number of advanced imaging systems.
3Chemical degradation of a fluorophore resulting in absence of fluorescence [47].
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Light microscopy
The main components in a light microscope are the light source, the condenser
lens, the objective lens and the eye piece [47]. The light source in a conventional
light microscope is usually a halogen bulb that emits white light. The light from
this lamp is focused on a small area of the sample by the objective lens. This results
in a magnified real image of the object in a image plane as shown in Figure 2.13.
Typical magnifications in the objective lens is in the range of 4× to 100×. The
image is subsequently magnified by the eye piece, which creates the resulting image
on the retina. The total magnification is given by the product of the magnification
in the objective lens and the magnification in the eye piece.
Figure 2.13: Focusing of light by an objective lens results in a magnified real image of the object
which can be imaged by the ocular. Adapted from [48].
A modern light microscope usually combines various lenses to improve the
magnification and the image quality by correcting lens irregularities and chromatic
aberrations. Optimal illumination of the sample is obtained when the sample is
evenly illuminated in the field of view, and the sample is illuminated with a cone of
light that is as wide as possible. These criteria are fulfilled using Köhlers illumination
principle [47].
The lateral resolution d of a microscope is defined as the shortest distance
between two points in the object which can be separated to be observed as two
separate points in the image. This will be limited by diffraction, and is given by the
Rayleigh criteria [47]:
(2.6) d = 0.61λ
NA
,
where NA is the numerical aperture and λ is the wavelength of light. The numerical
aperture is determined by the refraction index n of the media between the sample
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and the objective, and the maximal angle θ the light rays can have relatively axis
normal on the objective lens and still reach the objective as,
(2.7) NA = n sin(θ).
The thickness of the slice of the sample that is in focus is given by the axial
resolution Z in the objective plane, as
(2.8) Z = nλ
NA2
,
and can be improved with increased magnification in the objective and eye piece.
Inverted microscope
One of the problems in conventional microscopy is the limited working distance
between the object table and the objective lens. Objective lenses with magnification
in the range of 25× to 40× yield working distances of 3 to 5 mm [48]. Inverted
microscopes get an increased workspace since in an inverted microscope the light
source and the condenser are located above the object table, and the objective lens
is placed under the object table. In addition, gravity will facilitate the imaging, for
example in the case of imaging cells in the bottom of growth bottles or Petri dishes.
A disadvantage with inverted microscopes is that they have a more complex structure
and lower maximum magnification compared to the conventional microscopes.
Fluorescence microscopy
In fluorescence microscopy, a mercury or halogen lamp excites fluorophores in the
sample. By using an excitation filter, the wavelength of the light can be adjusted to
the excitation wavelength of the used fluorophore. Then the emitted light is detected
with a system of filters and dicromatic mirrors that separate the fluorescent light
from the excitation light. This separation is possible because, as mentioned before,
the fluorescent light have longer wavelength than the excitation light.
An important advantage of fluorescence microscopy is that it gives a high
signal-to-noise ratio which permits the detection of low concentrations of the molecule
under investigation [47]. In fluorescence microscopy epi-illimination can be used
since the fluorescent light has longer wavelengths than the excitation ligh. The sam-
ple is then illuminated with excitation light through the same lens that detects the
fluorescent signal. The excitation light and the fluorescent light are separated by a
dichromatic mirror that only allows light with wavelengths above a specific value to
pass through and the rest of the light is reflected.
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Chapter 3
Materials and methods
3.1 Experimental schedule
The experiment started with the preparation of the window chambers in the dorsal
skinfold of the mice and the spheroids were implanted inside the chamber and the
first light and fluorescence microscopy images (GFP images) of the chamber were
acquired. This day was considered day zero. From the first light and GFP images of
the implanted spheroids, the mice were divided into two groups: one that would be
treated with the cyclic hypoxia gassing and the other used as control, attempting to
keep both groups without any particular difference, i.e., same number of individuals
per group and implanted spheroids of approximately similar sizes between the two
groups. Once the two groups were separated the mice were kept in different cages
marked with their batch number and if they belonged to the control or the treatment
groups.
Table 3.1: Timetable for the experimental procedure.
Day: Tasks:
0 Insertion of window chambers in dorsal skinfold of mice.
Implantation of spheroids in chambers for both groups:
control and treatment. First GFP and light microscopy
pictures of the two groups.
1 to 9∗ 4 h. cyclic hypoxia exposure to the treatment group.
∗GFP and light microscopy on days 3 and 7 to assess
progression of treatment and control groups.
10 Filming of BST videos and last acquisition of GFP and
light microscopy images (treatment + control mice).
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As shown in Table 3.1, every day from day 1 to day 9 of the experiment, mice
in the treatment group were exposed to 4 hours of cyclic hypoxia. On days 3 and
7, light microscopy and GFP pictures were acquired for each mouse in both, the
treated and the control groups. The last day of the experiment was the day 10, on
this day the last light and GFP images were acquired and the filming of the videos
was effectuated. After completing the video and image acquisition, the mice were
sacrificed by neck dislocation before waking up from the anesthesia.
3.2 Cells and multicellular spheroids
A-07 human melanoma cells transfected with green fluorescent protein (GFP) by
lipofection were utilized for the experiments. These cells were obtained from a micro-
metastasis of malign melanoma in a patient at The Norwegian Radium Hospital.
Multicellular spheroids of the A-07-GFP cells were generated and maintained by
the liquid-overlay assay as in [49].
The tumor cell spheroids were cultivated in T75 cell flasks (Nunc, Denmark)
with agar bottom to prevent the cells from sticking to the bottom. Additionally,
30 ml of growth medium was added to each bottle. The medium consisted of 500
ml RPMI-medium, plus 75 ml of BSA R© (E. Pedersen & Sønn, Norway), 2.5 ml
of L-glutamin (Invitrogen, Denmark), 5 ml of penicillin/streptomycin (Invitrogen,
Denmark) and Geneticin R© (Invitrogen, Denmark). A gene with antibiotics resis-
tance against geneticin was added to the GFP-gene to prevent the growth of cells
without GFP. The cell bottles were placed on a tilt the first 3-4 hours after the seed-
ing. This initiated spheroid growth by helping the cells stick together. The day after
the seeding, single cells and longer chains of cells were removed by a pipette and it
was added 15 ml of new medium. The spheroids were controlled in a microscope
and the medium was changed once a week.
After all the window chambers were implanted in mice, the spheroids were har-
vested. At the harvest, the spheroids were transferred with a sterile glass pipette to a
flask with 10 ml HBBS buffer without CaCl2 or MgCl2 (Invitrogen, Denmark). Then
the flask with the spheroids was put on ice to keep them cold until the implantation
time.
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3.3 Mice
Adult female BALB/c nu/nu mice, approximately 8 weeks old, were used for
the experiments in this work. These mice were bred at the animal facility at the
Norwegian Radium Hospital under specific pathogen-free conditions, at a constant
temperature of 25±1◦C and humidity of 40±10%. Mice were fed with sterilized food
and water ad libitum. After implantation of window chambers, mice were transferred
to a scantainer cabinet with a constant temperature of 31◦C and humidity between
60 and 70% in order to compensate the increased heat loss at the edges of skin
surrounding the window chambers.
Breeding, care and experimental procedures were done in accordance to na-
tional rules for Laboratory Animal Science as well as with the Interdisciplinary Prin-
ciples and Guidelines for the Use of Animals in Research, Marketing and Education
(New York Academy of Sciences, New York, NY, USA).
3.4 Anesthesia
Before the surgical procedure for the implantation of the window chambers and
the spheroids, mice were anesthetized by either i.p. or s.c. injection of a mixture of
Hypnorm R© (0.315 mg/ml fentanyl citrate and 1 mg/ml fluanisone, Veta Pharma Ltd,
UK), and Dormicum R© (5 mg/ml midazolam, Roche, Switzerland). The proportions
for the mixture were one part of Hypnorm R©, one part of Dormicum R© and two parts
of sterile water, and the dosage of the mixture was 0.008 ml/g of body weight.
After the surgical procedures, the mice received an i.p. injection of 0.1 ml
of 1:10 dilution in saltwater of the analgesic Temgesic R© (buprenorphine, Schering-
Plough, Brussels, Belgium) which relieved the pain for the posterior 4 to 8 hours.
3.5 Window chamber preparations
Prior to the implantation of the window chambers, the mice were anesthetized
as described above. Then their skin was washed carefully with chlorine hexidin,
and the mice were placed on a sterile operation cloth. The sagittal center line and
the desired axial placement of the chamber were marked on the skin with a pen.
Since the vascular network is symmetrical at the sagittal axis, it was assessed that
the center line was correctly drawn by lifting the flip of skin on the back, placing
the two skin layers against each other until the vascular network in the skin layers
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overlapped. In order to fixate the flick of skin for the implantation of the chamber,
the dorsal skinfold of mice was sown to an in-house-made holder (Produced at the
workshop of the Norwegian Radium Hospital) with a surgical silk suture.
A circular perimeter with a diameter of 6 mm (same size of the transparent
window) was marked with a pen on one of the sides of the dorsal skinfold. Then, a
circular hole in one skin layer was made with a pair of surgical scissors within the
marked circular area. This was done to uncover the vascular network on the opposite
skin layer. A layer of nerves and fat on the exposed skin was removed in order to
obtain a higher quality in the microscopy images. Three holes were made with a
punch biopsy cutter evenly distributed around the exposed circular area. These holes
were made to attach the two parts of the chamber together with screws. Then the
front and back parts of the chambers were assembled, screwed together, and sown
to the skin with surgical silk suture, ensuring that skin was not squeezed together so
that the blood supply was not altered. Throughout the operation, physiological salt
water was used to humidify the skin in the exposed area to prevent drying in the
prepared skin layer. After the chamber was sown to the skin, the covering glass was
carefully attached checking that air bubbles had not formed under the glass. Then,
a rubber ring slightly larger than the glass covering the chamber was placed over
the latter with the help of tweezers. An Ω-ring (as the one illustrated in Figure 3.1-
Right) was placed with a specially designed set of pliers in order to fix the glass to
the chamber. After completing the surgical procedure, the wounds were lubricated
with 2% Fucidin R© (Leo Pharma A/S, Norway) and 0.1 ml Temgesic R© was injected
i.p. in the mice to relief possible pain for the next 4-8 hours.
Figure 3.1: Left: BALB/c nu/nu mouse with a dorsal intravital chamber. Right: Illustration of
a dorsal window chamber showing the ideal placement of an spheroid (marked in green) in relation
to the reference vessel (marked in red).
The implantation of the spheroids was done immediately after preparing the
window chambers. As shown in Figure 3.1, the chambers were placed so that an
artery was visible in the periphery of the window. The purpose of this placing was to
later use the artery as a reference for calculating the blood supply times in the tumor
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vasculature as well as allowing the tumor to grow in the largest possible space within
the chamber. The ideal location to implant the spheroid in the window chamber is
also illustrated in Figure 3.1-Right. The spheroid is not positioned in the center of
the window chamber because it has been observed that the skin have a tendency to
lose stiffness and move towards the lower part of the window chamber in previous
experiments. A photograph of a mouse carrying a dorsal window chamber is shown
in Figure 3.1-Left.
3.6 Hypoxia treatment
The animals in the treatment group were subjected to a 4 hour cyclic hypoxia
treatment everyday from day 1 to day 9 of the experiment. The daily treatment
consisted of 12 periods of 10 minutes breathing a mixture with 8% oxygen and 92%
nitrogen (hypoxia gas mixture), alternating with 10 minutes of breathing normal
air. An illustration of the intended changes in oxygen concentration as a function
of time is shown in Figure 3.2.
Figure 3.2: Cycles of hypoxia and normal air exposure in the gas chamber. Daily treatment
consisted of 12 periods of 10 minutes exposure to 8% oxygen concentration gas alternating with
10 minutes exposure to normal air, giving a daily treatment time of 4 hours. The figure illustrates
two of the 12 periods in a daily treatment.
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The cycles were regulated by electronically controlled valves. The first valve
was open for two minutes to allow the hypoxia gas to flow into the chamber, the
valve was then closed for the next 18 minutes. After 10 minutes, the second valve
opened for 2 minutes allowing 21% O2 to fill the chamber. This cycle was repeated
for 4 hours.
Figure 3.3: Cyclic hypoxia exposure chamber set-up diagram. Electronically controlled valves
regulated the inflow of gas. A control-limit was programmed to open and close the valves in
order to get the desired hypoxia treatment (Fig. 3.2). The gasses were humidified in flasks with
water before continuing their way into the gassing chamber. Inside the chamber, mice were placed
in a normal cage, and were allowed to eat and drink ad libitum. A device that measured the
oxygen concentration in the air was placed inside the gas chamber in order to monitor the oxygen
concentration throughout the cycles.
As illustrated in Figure 3.3, both, hypoxia gas and air, were humidified by
flushing through flasks with water. This was done in order to prevent irritation
due to drying of the mucosa in the mice. The gassing chamber consisted of an
in-house-made acrylic box. This box had a circular hole with a radius of 1 cm to
allow flushing of the gas content when a different gas comes into it. Inside the gas
chamber, mice were placed in a normal cage and were allowed to eat and drink
ad libitum. Additionally, a device that measured the concentration of oxygen was
placed inside the gassing chamber to monitor the oxygen concentration throughout
the cycles.
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3.7 Microscopy imaging
3.7.1 Microscope set-up
An IX71 Olympus R© inverted microscope (Olympus, Japan) was used for the ac-
quisition of images. The objective lenses used had had a magnification of 2× and
4×. This microscope was equipped a mercury lamp and various filter packages for
detection of fluorescent light. GFP-images were taken with the filter packageNIBA,
and TRITC-images with the filter packageWIY . The detection system consisted of
a black and white C9300-024 Hamamatsu R© CCD-camera (Hamamatsu Photonics
K.K., Japan) and the image acquisition softwareWASABI R© (Hamamatsu Photonics
K.K., Japan).
While acquiring the images and videos of the tumors, a hot air blower (pro-
duced at a workshop in Radiumhospitalet) was used in order to maintain the normal
body temperature of the mice by blowing air with a constant temperature of 37◦C.
The importance of this addition relies on the fact that reduced body temperature
not only can affect the mice vitality but also can result in vessel contraction and
changes in the blood flow.
3.7.2 First-pass imaging of tumor vasculature
A 0.2 ml bolus of TRITC-dextran (tetra-methylrhodamine isothicyaneate-dextran)
of a molecular weight of 155 kDa, diluted to a concentration of 50 mg/ml in physi-
ologic salt water was injected in a lateral tail vein. This bolus was used as vascular
tracer for first-pass imaging. The time resolution of the movies was 22.3 fps.
The movie was acquired using the 2× objective in order to include the whole
tumor as well as the reference artery in the field of view. Before filming the vascu-
lature, normal light transmission and GFP images were taken. The exposure time
chosen for the movie was 40.0 ms, resulting in a combination of exposure time,
volume, and concentration of TRITC-dextran that has earlier been shown to give
optimal exposure of the movie [50]. During the filming, the lights in the room and
the microscope regular lamp were off. After choosing the correct filter for TRITC-
dextran, the shutter that blocked the excitation light from the mercury lamp was
opened and the video acquisition started as the TRITC-dextran bolus was injected.
After filming for 30 seconds, the video acquisition was stopped and the shutter was
closed in order to prevent photo bleaching and overheating of the chamber in the
mouse.
34 CHAPTER 3. MATERIALS AND METHODS
3.7.3 Morphology images
An objective lens with a 4× magnification was used in order to obtain images
of the tumor vasculature with better spatial resolution. However, this resulted in a
smaller FOV and for some large tumors more than one image had to be acquired and
patched together to cover the entire tumor. The morphology images were acquired
immediately after the video filming was completed. Light microscopy was used to
focus the image and the choose the FOV. For every tumor or region of it (in the
case of large tumors that required more than one image) light microscopy, GFP and
TRITC images were acquired. The optimal exposure time was chosen individually
for every image. The images were stored in TIFF format (Tagged Image File Format)
for further analysis. The image quality control, and the analysis of the intensities
in the pixels in every frame was executed using AquaCosmos R© 2.5 (Hamamatsu
Photonics K.K., Japan) software.
3.8 Data analysis
3.8.1 BST
The blood supply time, BST, is a functional parameter of the vascular network
defined as the time difference between the maximum fluorescence intensity in a pixel
inside a blood vessel and the maximum fluorescence intensity in the main supplying
artery (MSA) of the tumor.
Figure 3.4: BST assignment method. The MSA of the tumor is chosen as reference for the BST
in all the pixels of the tumor vasculature: the time difference between the maximum fluorescence
intensity in the MSA and the maximum fluorescence intensity in a specified pixel of a capillary will
be the BST of that pixel.
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Figure 3.4 illustrates the determination of the BST: First, an artery that sup-
plies the tumor is chosen as reference. The time of maximum fluorescent intensity in
the MSA is defined t = 0. The pixels within the tumor vasculature will have a time
of maximum fluorescent intensity a certain time after the MSA. This time difference
is defined as BST.
The BST was calculated for every pixel in the image using a program developed
in IDL R© (Interactive Data Language, Research Systems Inc., Boulder, USA) at the
Department of Radiation Biology at the Norwegian Radium Hospital. The reference
value was determined by calculating the average in a circular ROI in the reference
artery. The BST-value was then extracted from all the pixels within the vascular
network by applying the vascular mask. The vascular mask was established from
a maximum trace image consisting of the maximum fluorescence intensity in each
pixel throughout the film [51].
3.8.2 Morphology
For quantitative analysis of the morphology of tumor vascular networks, masks
of the vasculature were created. This masks were obtained in MATLAB R© (The
MathWorks, Inc., USA) by running a program developed at the Department of Ra-
diation Biology at the Norwegian Radium Hospital, with the assistance of Norsk
Regnesentral. The program consists in the application of a white top-hat transform,
which removes contributions from light background noise, afterwards, the images are
eroded with linear structure elements before effectuating local thresholding. This
yields a binary image of the vascular network, where the pixels comprised in the
vessels are set to 1 and the rest to 0. From the vascular masks the morphologi-
cal parameters: vascular length density, vascular area fraction, interstitial distance
and vessel diameter were calculated by in-house-made algorithms developed at the
Department of Radiation Biology at the Norwegian Radium Hospital [52].
3.8.3 Tumor growth
The area of the tumors was obtained in AquaCosmos R© 2.5 (Hamamatsu Photonics
K.K., Japan) by manually drawing the tumor perimeter on the GFP-images.
3.8.4 Statistical analysis
The statistical analysis and plotting of the data was effectuated using SigmaPlot R©
(Systat Software Inc., USA) andMATLAB R© (The MathWorks, Inc., USA). The data
was compared by the student t-test using a significance criteria of p < 0.05.
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Chapter 4
Results
4.1 Oxygen concentration in gas chamber
Before mice were exposed to cyclic hypoxia, the experimental set-up was tested.
the desired hypoxia treatment consisted of cycles of 10 minutes exposure to 8% of
oxygen alternating with 10 minutes exposure to normal air (20.9% O2). In order
to test the system, a device that measures the oxygen concentration in air was put
inside the gas chamber, and the oxygen concentration was recorded for two cycles.
This was plotted in Figure 4.1.
Figure 4.1: Oxygen concentration in the gas chamber as a function of time for two cycles.
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Figure 4.2: Top: Concentration of oxygen in the gas chamber as a function of time, during filling
of the chamber with hypoxia gas for two minutes and 8 minutes afterwards in two different cycles.
Bottom: Oxygen concentration in the gas chamber versus time, during filling of the chamber
with air for two minutes and 8 minutes afterwards, in two different cycles that followed a period
of hypoxia gassing.
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Another requirement to be fulfilled was that the cycles in either the hypoxia
gas or the air exposure were similar to each other, i.e., that the increase and decrease
in the oxygen content inside the chamber for one cycle did not vary significantly for
the same process at a different time. For this reason, in Fig. 4.2, two hypoxic and
two air gassing cycles were plotted overlapped as a function of time, respectively.
From these plots, it is possible to see that the cycles were reproducible and the
desired oxygen concentration was reaches approximately one minute after the valves
were opened.
4.2 Implanted spheroids
As part of the quality control in this experiment, it was required that the size of
the implanted spheroids did not vary significantly between the two groups (both,
treatment and control groups consisted of 10 tumors each). Because of this, the
area of the implanted spheroids was measured from the first fluorescence microscopy
images (GFP images) and plotted in Figure 4.3.
Figure 4.3: Area of the spheroids measured from the GFP images acquired right after their
implantation. The horizontal line represents the average in the area of the implanted spheroids for
each group. The difference between the treated and control groups was not significant (p > 0.05).
Moreover, a student t-test was effectuated to compare the groups. According
to the t-test, the difference in size of the implanted spheroids between the two groups
was not of statistical significance (p > 0.05).
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4.3 Tumor growth
Tumor growth was quantified by measuring the area of the tumors from the flu-
orescence microscopy images (GFP images), since in these ones the contrast given
by the GFP makes easier to delimit the tumor.
Figure 4.4: Left panels: Light microscopy images of a representative treated tumor on days 0,
3, 7 and 10, respectively from top to bottom. Right panels: GFP images of the same tumor at
the same time than in the picture in the left. The scale bar represents 1 mm.
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Figure 4.5: Left panels: Light microscopy images of a representative control tumor on days 0,
3, 7 and 10, respectively from top to bottom. Right panels: GFP images of the same tumor at
the same time than in the picture in the left. The scale bar represents 1 mm.
Figure 4.4 shows the growth of a representative treated tumor. In the top
part, the light microscopy images are shown. From these, one can see the normal
vasculature in the surroundings of the implanted spheroid and how the vessels are
slightly moved towards the tumor after this latter has began the angiogenic process.
In the GFP images (bottom), is possible to see how the growth rate of the tumor
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seems to increase more rapidly with time. The same can be observed in Figure 4.5,
where a representative control tumor is shown. However, the control tumors seemed
to increase in size faster than the treated ones. In order to get a more objective
appreciation of these apparent differences in growth rate, the size of the control and
the treated tumors was plotted as a function of time as presented in Figure 4.6.
Figure 4.6: Tumor area of treated and control tumors from the day the spheroids were implanted
in the window chambers until the last day of the experiment. Each point represents the mean of
10 tumors, and the error bars correspond to the standard error of the sample.
Figure 4.7: Tumor area at the end of the experiments for treated and control tumors. The
horizontal line represents the average value of the tumor size for each group (∼ 6.99 mm2 for the
treated tumors and ∼ 9.55 mm2 for the control tumors). The difference between the growth in the
two groups is significant (p = 0.045).
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To confirm if the tendency in the growth rate difference was significant, tumor
area of the treated and control tumors at the last day of the experiments was plotted
and is shown in Figure 4.7. The student t-test was used to compare both groups
and yielded a p-value of p = 0.045, therefore, the differences in tumor area at the
end of the experiment between the treated tumors (6.99 ± 2.91 mm2) and control
tumors (9.55± 2.35 mm2) was statistically significant.
4.4 Vascular morphology
The vascular masks produced from high-resolution images of the tumors (×4 ob-
jective lens) as binary images. Since the parameters describing the tumor vascular
morphology were computed from these masks, it was important to verify that the
masks kept indeed the characteristics of the vascular network in the tumor.
Figure 4.8: Left: TRITC-dextran intravital microscopy image of a representative treated tumor
acquired with a ×4 objective lens. Right: Mask of the vascular network of the same tumor
produced from the TRITC-dextran image.
Figures 4.8 and 4.9 show the vascular networks of representative treated and
control tumors, respectively. In the left side, the TRITC-dextran images of the
tumors are shown and in the right side, the binary mask of the tumor vasculature.
From these images, heterogeneities in vessel density are noticeable, with apparent
higher density in the periphery than in the center of the tumor, this is specially
evident in the control tumor (Fig. 4.9). These heterogeneities in vessel density are
quantified in the following section. The general quality of the vascular masks was
comparable to that of the tumors shown these images.
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Figure 4.9: Left: TRITC-dextran intravital microscopy image of a representative control tumor
acquired with a ×4 objective lens. Right: Mask of the vascular network of the same tumor
produced from the TRITC-dextran image.
4.4.1 Vessel density
The vessel density parameters calculated from the tumor vascular masks were the
vascular length density, the vascular area fraction and the interstitial distance.
Vascular length density
The vascular length density is a parameter of the microvascular density in the
tumor defined as the total vessel length per µm2 of tumor area. Figure 4.10 shows
the results of computing the vascular length density in the tumors treated with
cyclic hypoxia and the control tumors. From this plot, a trend towards higher
vascular length density in the treated tumors is evident, however, the comparison
of the two data groups yielded a p-value of p = 0.194, and thus, the difference can
not be considered significant. The vascular length density in the treated tumors
ranged from ∼0.018 to ∼0.025 µm/µm2, with an average value of 0.0214 ± 0.0021
µm/µm2; whereas the control tumors had vascular length densities between ∼0.0178
and ∼0.0238 µm/µm2 and had an average value of 0.0202± 0.0018 µm/µm2.
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Figure 4.10: Vascular length density of the treated and control tumors. The horizontal lines
represent the average values (∼0.214 µm/µm2 and ∼0.0202 µm/µm2 for the treated and the control
tumors, respectively). The difference between the two groups of tumors was not statistically
significant for this parameter (p > 0.05) in spite a trend towards higher values in treated tumors.
Vascular area fraction
The vascular area fraction (VAF) is a dimensionless parameter of the vascular
density in the tumor defined as the ratio of the number of pixels within the vascular
mask to the total of pixels comprised in the tumor area.
Figure 4.11: Vascular area fraction (VAF) of the treated and control tumors. The horizontal lines
mark the average values (∼0.421 and ∼0.402 for treated and control tumors, respectively). The
difference in the VAF between the two groups of tumors was statistically significant (p = 0.046).
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Figure 4.11 shows the vascular area fraction of tumors that were exposed to
cyclic hypoxia treatment and control tumors. The treated tumors had vascular area
fractions between ∼0.389 and ∼0.457, and an average of 0.421± 0.019. Conversely,
the control tumors had vascular area fractions ranging from ∼0.381 to ∼0.438, with
a mean value at 0.402± 0.019. The p-value obtained from the t-test was p = 0.046,
hence, it can be said that the VAF in the treated is significantly different from
the VAF in the control tumors. This indicates that tumors subjected to cyclic
hypoxia developed vascular networks with higher vessel density than the tumors
under normal conditions.
Interstitial distance
The interstitial distance was defined as the average distance from a pixel in the
tumor that does not belong to the vascular network to the closest pixel inside the
vascular mask. Figure 4.12 shows the mean interstitial distances in treated and
control tumors. The tumors in the mice subjected to the cyclic hypoxia treatment
showed significantly shorter interstitial distances than the tumors in the control
group, with a p-value of p = 0.034. The interstitial distances in the treated tumors
ranged from ∼12.4 µm to ∼16.4 µm with the mean value of 14.2 ± 1.2 µm. The
control tumors though had interstitial distances ranging from ∼13.9 µm to ∼19.0
µm, with a mean value of 15.7± 1.3 µm.
Figure 4.12: Interstitial distance in the vascular networks of the treated and control tumors. The
horizontal lines correspond to the average values (∼14.2 µm and ∼15.7 µm for the treated and the
control tumors, respectively). The difference in the interstitial distance between the two groups of
tumors was statistically significant (p = 0.034).
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Figure 4.12 indicates that the vessels in the tumors that were exposed to the
cyclic changes in oxygen tension were more closer together than the vessels in the
control tumors.
4.4.2 Vessel diameter
The vessel diameter of the tumors was calculated as the average of the diameters
of all the vessels in the vascular mask. This is plotted in Figure 4.13 for the treated
and the control tumors. There was no significant difference between the treated and
control tumors (p = 0.791) and no clear trend was noticeable. However, the mean
values of vessel diameter were more spread for the treated tumors, ranging from
∼20.68 to ∼26.11 µm, whereas the control tumors ranged in vessel diameters from
∼21.52 to ∼25.27 µm. The average values of the vessel diameter were 23.27 ± 1.7
µm for the tumors treated with cyclic hypoxia and 23.46± 1.42 µm for the control
tumors.
Figure 4.13: Mean vessel diameter in the treated and control tumors. The horizontal lines
represent the average values (∼23.27 µm and ∼23.46 µm for the treated and the control tumors,
respectively). There was no significant difference between the two groups of tumors (p > 0.05).
4.4.3 Intratumor heterogeneity
It was observed that most of the control tumors displayed spatial heterogeneities
in the vessel densities, tending to a lower vascular density in the central region. This
tendency was not so clear in the hypoxia treated tumors. The tumors were divided
into two concentric regions of interest (ROIs) delimited by lines traced at distances
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of 2R/3 and R from the center of the tumor, where R is the radius1 of the tumor. An
example of this division into peripheral and central ROIs of the morphology images
of the tumors is shown in Figure 4.14.
Figure 4.14: Division of the morphology images of the tumors into two ROIs: a central ROI
delimited by a line drawn at 2R/3 and a peripheral ROI between the lines at 2R/3 and at R, where
R is the tumor radius. Top: TRITC-dextran image acquired with a ×4 objective lens of a tumor
in the control group showing the division of the ROIs. Bottom: TRITC-dextran image acquired
with a ×4 objective lens of a tumor subjected to cyclic hypoxia treatment, showing the division of
the concentrical ROIs.
1At a certain angle in a polar coordinate system with origin in the tumor center.
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Vascular area fraction in the central ROI
The vascular area fraction in the center of the treated and control tumors is
plotted in Figure 4.15, where it is evident that the tumors in the mice subjected to
the cyclic hypoxia treatment had higher VAF in this ROI (0.414 ± 0.02) than the
control tumors (0.394± 0.016). These differences were statistically significant, with
a p-value of p = 0.032. This difference in vessel density was larger for the central
ROI than for the entire tumor (lower p-value p = 0.032 vs. p = 0.046).
Figure 4.15: Vascular area fraction in treated and control tumors in the central ROI. The
horizontal line corresponds to the mean values (0.414 and 0.394 for the treated and control tumors,
respectively). The difference between the two groups was statistically significant (p = 0.032).
Vascular area fraction in the peripheral ROI
The peripheral ROI comprised the area within 2R/3 and R of the tumor. The
vascular area fraction in the peripheral ROI of the tumors that underwent the cyclic
hypoxia treatment and the control tumors is shown in Figure 4.16.
The results show a tendency to higher VAF in the periphery of the treated
tumors (with an average of 0.418 ± 0.0148) than in the periphery of the control
tumors (average value of 0.408±0.020), however, the difference was not statistically
significant (p = 0.225). It is also noticeable from both, the plot and the standard
errors, that the values of the VAF in this ROI had a larger spread for the control
tumors than in the treated tumors. The difference in vessel density was smaller for
the peripheral ROI than for the entire tumor (higher p-value p = 0.225 vs p = 0.046).
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Figure 4.16: Vascular area fraction in cyclic hypoxia treated and control tumors for peripheral
ROI. The horizontal line corresponds to the mean values (∼0.418 and ∼0.408 for the treated and
control tumors, respectively). There was no significant difference in the VAF for the peripheral
ROI between the two groups of tumors (p > 0.05), yet, a tendency towards higher VAF in the
periphery of treated tumors is apparent.
Hence, tumors treated with cyclic hypoxia developed a more homogeneous
vasculature throughout the whole tumor than the control tumors.
4.5 Vascular function
4.5.1 BST
The top panels of Figure 4.17 show frames of a first pass imaging movie of a tumor.
The frames correspond to ∼1, 3 and 15 seconds after i.v. injection of the TRITC-
dextran bolus in the mouse. In the three frames, the main supplying artery (MSA), a
tumor arteriole (TA), a tumor capillary (TC) and a tumor venule (TV) are marked.
The relative fluorescence intensity of the selected pixels corresponding to the MSA,
TA, TC and TV was plotted as a function of time (Fig. 4.17, lower panel). All
the vessels showed well-defined peaks in the fluorescence intensity vs. time curves,
and the time of maximum fluorescence intensity varied among the different vessels,
corresponding to different blood supply times (BST).
BST maps and histograms
Once all the pixels in the vascular network of the tumors have a BST-value as-
signed, color BST maps can be produced by representing the time scale as a color
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Figure 4.17: Blood supply times of different vessels in a tumor. Top panels: Frames of a first
pass imaging of a tumor corresponding to approximately 1, 3 and 15 seconds after injection of the
TRITC-dextran bolus respectively. The main supplying artery (MSA), a tumor arteriole (TA), a
tumor capillary (TC) and a tumor venule (TV) are marked on the frames. The scale bars in all the
frames represent 1mm. Bottom: Relative fluorescence intensity of the selected pixels (marked in
the images) as a function of time. The time scale has been adjusted to make t = 0 when the MSA
has its maximum fluorescence intensity.
scale. This is shown in the left panels of Figures 4.18 and 4.19, where the red color
indicates low BST values in the pixels whereas the blue color correspond to pixels
with high BST values.
It was observed that the tumors in the mice subjected to cyclic hypoxia dis-
played larger variations in BSTs, as shown in the left panels of Figures 4.18 and
4.19. Thess heterogeneities can be better appreciated in the histograms of the BST
values in all the pixels of the vascular networks (see the right panel of Figures 4.18
and 4.19). The broader the histogram, the more heterogeneous the tumor is in BST.
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Figure 4.18: Left: Blood supply map of a representative treated tumor. The timescale, symbol-
ized by the colorscale, is linear and ranges from 0.0 to 4.0 seconds. The scale bar corresponds to
1 mm. Right: Histogram of the blood supply times in this tumor, the vertical bar corresponds to
the median BST (∼ 2.15 s).
Figure 4.19: Left: Blood supply map of a representative control tumor. The timescale, symbol-
ized by the colorscale, is linear and ranges from 0.0 to 4.0 seconds. The scale bar corresponds to
1 mm. Right: Histogram of the blood supply times in this tumor, the vertical bar corresponds to
the median BST (∼ 1.4 s).
A BST map of a control tumor is shown in Figure 4.19-Left. This tumor is
representative among the control tumors in the fact that the vascular network was
more efficient, i.e. the transit of the bolus of TRITC-dextran not only occurred
faster, but also presented less variations throughout the tumor. This reduced het-
erogeneity was verified in the histogram (Fig. 4.19-Right), where a well defined peak
appears around the median value of the BSTs within the vasculature of this tumor.
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BST in treated and control tumors
Lastly, the median values of the BST in each tumor of the cyclic hypoxia treated
and control groups was plotted, as shown in Figure 4.20. The median BST values
in the tumors treated with cyclic hypoxia ranged from 1.25 to 2.40 seconds, and the
median BST in the control tumors ranged from 0.85 to 2.19 seconds. The mean
values of the BST medians in the tumors were 1.94± 0.51 and 1.51± 0.56 seconds
for the treated and the control tumors, respectively.
Figure 4.20: BST median values for the treated and control tumors. The horizontal bar corre-
sponds to the mean value of the BST medians in the treated (1.94 s.) and the control (1.51 s.)
tumors. A tendency to higher BST values in the treated tumors was visible, however the difference
was not statistically significant (p = 0.148).
From Figure 4.20, it is noticeable a tendency towards higher BST values in the
tumors that were subjected to cyclic hypoxia. Nevertheless, this apparent difference
between the treated and control tumor groups was not statistically significant (p =
0.148).
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Chapter 5
Discussion
5.1 Discussion of materials and methods
5.1.1 Tumor model
Xenografts
The experiments in this work were effectuated on immunodeficient mice with hu-
man melanoma xenografts. One of the limitations of using xenografts in research is
that after the implantation of the cells in the animal, the vascular network in the
tumor will be recruited from the host animal. This might be a problem when inter-
preting parameters related to the features of the vasculature since blood vessels in
the host animal can respond differently to the disrupted balance between angiogenic
inhibitors and stimulators. Another important limitation when using xenografts in
cancer research is that the immunodeficiency of the host animal is a factor that can
permit greater tumor growth rates than in individuals with a normal immunological
system. This increase in tumor growth rate could be an advantage experimentally
since the experiments can be terminated in shorter time. Yet, the increased growth
rate in tumors can influence the development of the vascularity, and the results on
experiments that are sensitive to tumor growth rates [29].
In spite of the limitations, xenografts can provide valuable information of the
vascularity and blood flow in tumors. There is evidence that xenografts can be
adequate tumor models, for example, Rofstad showed that xenografts maintain the
histological characteristics from the original tumor [44]. Moreover, the response to
radiation therapy, chemotherapy and hyperthermia in xenografts is similar to the
response in the original human tumors [29, 44].
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Cell line and spheroids
Multicellular spheroids of A-07-GFP cells were implanted in the window chambers
in the mice. The sizes of the implanted spheroids varied from one mouse to another,
however, it was supervised that at the moment of dividing the mice in the control and
treatment groups, the differences in the implanted spheroid sizes were not significant.
This was done to ensure that the observations in growth rate between the two groups
of mice were not affected by the differences in the sizes of the spheroids.
A limitation with the use of spheroids is that, in order to emulate spontaneous
tumors that arise from a single mutated cell, spheroids should contain very few cells.
However, smaller spheroids are more likely to be rejected through immune reactions
in the host animals. This can happen even in immunodeficient animals.
Since it was wanted to observe the effects of cyclic hypoxia in the tumors, it
was important to discard the presence of diffusion-limited hypoxia in this tumor
cell line. This has been demonstrated by analyzing histological sections of A-07-
GFP tumors extirpated from the mice and dissected after injection of pimonidazole
(a well-known chronic hypoxia marker), and by comparing the radiation survival
curves of the same cell line irradiated in vitro under aerated conditions and the
cells in tumors of this same line irradiated in vivo. It was demonstrated by the two
methods that A-07-GFP tumors of under 100 mm3 of size (such as those used in
this Master Thesis experiments) do not present regions of chronic hypoxia [6].
Window chambers
The use of window chamber preparations has provided valuable information in
previous studies of blood flow in experimental tumors [46, 52, 53]. Nevertheless,
there are limitations with this method. One of these is the spatial restriction imped-
ing tumor growth in the direction of the window. It is important to notice that even
though, there is no spatial restriction in the back side of the chamber, the growth
of the tumor as a whole is affected, resulting in hemispherical tumors. Another
limitation is that as the tumor grows inside the window chamber and approaches
to the size of the window, the tumor will suffer an increased pressure which could
result in a reduced growth rate, among other possible consequences.
On the other hand, some of the advantages of the use of tumor window cham-
bers are that the windows permit the observation with microscopes of the vasculature
in the tumor. By using window chambers it is possible to monitor the tumor growth
rate as well as the development of the vascular network of the tumor with time.
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Window chambers also allow the acquisition of movies of the vascular function in
the tumors.
In these experiments, the window chambers were implanted in a position that
located an artery close to the edge of the window so that the tumor had sufficient
space to grow and that the artery appeared in the images and movies. Another im-
portant detail is that the experiment was planned taking into account usual growth
rates in the used tumor line, in order to prevent tumor growth outside the field of
view.
5.1.2 Cyclic hypoxia treatment
The animals in the treatment group were subjected to a 4 hour daily cyclic hypoxia
treatment. Each daily treatment consisted of 12 cycles of 10 minutes of only 8% O2
in N2 followed by 10 minutes of air breathing. This treatment was received for 9 days
starting at the day after the implantation of the window chambers and spheroids.
One of the reasons for choosing this schedule for the cyclic hypoxia treatment
is that it has been used previously for investigating the effects of cyclic hypoxia in
different tumor models [3, 4, 6]. (The 4 hour treatment choice is related to applica-
tion of oxic stress in the tumor but prevention of adaptation to this fluctuations in
the animal [3]. )
In addition, it has been shown that spontaneous fluctuations in oxygen con-
centrations occur cyclicly in experimental tumors, and that the duration of these
cyclic hypoxia periods ranges from less than one minute to several hours [25, 54].
This indicates that a choice of 10 minute periods of hypoxia gas exposure alternating
with 10 minutes of exposure to normal air is within a realistic range of what occurs
spontaneously in tumors that have not been subjected to hypoxia treatment.
In these experiments, the concentration of oxygen during the hypoxic periods
was chosen to be 8%. The exposure to this oxygen concentration is not dangerous
for the mice. In other experimental studies of the effects of cyclic hypoxia, mice have
been exposed to lower O2 concentrations during the hypoxic cycles, between 5-7%
of oxygen [3, 4, 55]. Rofstad et al. measured the oxygen concentration in tumors
with OxyLite probes during a cyclic hypoxia treatment identical to that used for
this thesis work, revealing that the exposure to 8% of O2 in the mice resulted in
a concentration of oxygen inside the tumor of 0% disregarding if the tumors were
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well- or poorly-oxygenated under normal conditions [6]. Thus, it has been proven
that exposure to 8% of oxygen induces hypoxia in tumors.
5.1.3 Vascular masks
Vascular masks for quantification of vascular morphology were produced from
the TRITC-dextran fluorescence images acquired with a ×4 objective lens with a
conventional microscope (described in Chapter 3). One limitation of imaging the
tumors with a conventional microscope is that this type of microscopes will get
in focus only a slice of the tumor, and all the regions that do not belong to this
slice will appear blurred thereby introducing background noise and giving a reduced
contrast in the image. This will happen because the tumors are three-dimensional.
The thickness of the slice of the tumor that is in focus in the image depends on the
wavelength of the fluorescent light, as well as the absorption and emission properties
of the tissue.
The use of a conventional microscope results in a projection of a 3-dimensional
vascular network into a 2-dimensional image. The contributions from the regions
out of the focus introduce uncertainty in the vascular masks and in the parameters
calculated from these masks. A consequence of looking at different depths of the
tumor simultaneously in the vascular masks could be an overestimated vessel density.
One possibility to avoid the projection of the whole tumor in two dimensions would
be to use a confocal microscope for the acquisition of the images. This limitation
would not occur with a confocal microscope since this type of microscopes only allow
the fluorescent light from the selected slice to reach the detector [47].
In spite of these limitations in the vascular masks, the noise was comparable
to what has been published previously by Gaustad et al. [52]. In this study it was
shown that vascular masks calculated by the same algorithm as used in this thesis
were comparable to the tumor vascular networks. In addition, as quality control for
the vascular masks, the similarity of the mask to the vascular network of the tumor
was assessed individually. Those vascular masks that presented regions that did not
reproduce the vessels in the tumor were corrected manually.
5.1.4 Calculation of BST
TRITC-dextran injected intravenously was used as a contrast agent for the first-
pass imaging of the tumors. A requirement that needed to be fulfilled for the cal-
culation of BST in the studied tumors was to get narrow and well-defined peaks
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of the fluorescence intensity versus time curves in every pixel. To achieve this,
TRITC-dextran needed to be injected fast, as a bolus. It is known though that fast
intravenous injections can result in a temporary increased blood pressure. However,
since the bolus was injected into a lateral tail vein, it is possible to assume that be-
fore the bolus reaches the vascular network, the pressure in the blood is equilibrated,
and that this increase is not significant when the bolus gets into the tumor vascula-
ture. One parameter that is hard to control is the time it takes to inject the bolus.
This injection time is most likely to have varied from one tumor to another, thereby
affecting the quality of the fluorescence intensity peaks. However, this variations are
expected to be small.
It has been shown in previous experiments that this BST calculation method
has a fine sensitivity when using a bolus of TRITC-dextran with the same charac-
teristics as the one used in this work [51]. As shown in the lower panel of Figure 4.17
the passing of the bolus in different vessels (main supplying artery, tumor arteriole,
tumor capillary and tumor venule) could be detected as well-defined fluorescence in-
tensity peaks. This means that the bolus can be followed in all the different vessels,
and therefore, it is possible to obtain BST values in all the pixels comprised in the
vasculature of the tumors.
A limitation of the BST parameter is that it does not give direct information
about the delivery of oxygen to the tumor cells. The TRITC-dextran bolus follows
the plasma current, however, the red blood cells are the component of the blood that
transports the oxygen to the tissue [56]. Since red blood cells cannot move faster
than plasma in the blood flow [20], BST represents a theoretical minimum time
for red blood cell supply. It could happen in thin capillaries that the circulation is
mainly conformed of plasma (local hemodilution) [20] and this cannot be detected
in the method for calculating the BST. Nevertheless, it has been shown that the red
blood cell flux not necessarily reflects the supply of oxygen in tumor tissue due to
the fast depletion for oxygen of erythrocytes inside the tumor vasculature [53].
For the calculation of BST, the time of maximum fluorescence intensity in the
main supplying artery (MSA) of the tumor was used as the time reference. A proper
choice of the pixels or ROI selected for reference in the MSA was important in order
to be able to compare the BSTs of different tumors. This is however not an easy
task, since it was desirable to select the reference at approximately the same vascular
distance from the tumor. Another limitation regarding the selection of the reference
in the MSA is that some big tumors had grown over the MSA thereby taking it out
of the focus when imaging, or totally impeding them from being observed in the
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movies. For this reason some tumors were discarded from the sample included in
the BST calculations. Only tumors with visible MSAs were used for quantification
of the BST.
Notwithstanding the limitations of the BST calculation method, all the tumors
(tumors treated with cyclic hypoxia and control tumors) were imaged in the same
way, and under the same conditions. Therefore, the limitations apply equally to all
the obtained data and the noise should be comparable for both groups of tumors,
and comparable to what has been published before in [52, 51] when applying this
same method for other investigations.
5.2 Discussion of the results
5.2.1 Vascular morphology
The morphological images of the tumors (Figures 4.8 and 4.9) give a qualitative
impression of the vasculature in the tumors. One difference that was evident from
the vascular masks was the higher vessel density in the tumors belonging to the mice
treated with cyclic hypoxia. Another feature that was visible from the morphology
images was the intratumor heterogeneity. This was specially evident in the control
tumors, in which a higher vessel density characterized the peripheral regions in com-
parison to the central region of the tumors. However, differences in vessel diameter
were not obvious from the images.
The vascular masks produced from the morphological images allowed the quan-
tification of the vessel length densities, vascular area fraction, interstitial distance
and vessel diameter. From these quantifications, qualitative differences observed
between the images of the morphology could be confirmed.
Vessel density
The parameters used for the quantification of the vascular density were the vas-
cular length density, the vascular area fraction and the interstitial distance.
The vascular length density (total vessel length per µm2) between the two
tumor groups (Fig. 4.10) showed a trend towards higher values in the tumors treated
with cyclic hypoxia. The vascular area fraction of a tumor (# of pixels within the
vascular mask / # of pixels in the whole tumor) was significantly higher for the
tumors subjected to cyclic hypoxia than for the control tumors (p = 0.046). This
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result has important implications supporting higher vessel densities in the treated
tumor. Lastly, the interstitial distance in the treated tumors was shorter than in the
control groups (p = 0.034). This means that the vessels in the tumors exposed to
cyclic hypoxia were closer together than the vessels in the control tumors, confirming
the evidence of higher vessel density in the treated than in the control tumors. It
is of relevance that the interstitial distances in all the studied tumors (treated and
control) did not exceed 20 µ m which is under the oxygen diffusion limit threshold
(100-200 µm), and therefore it is not probable that the studied tumors had regions
of chronic hypoxia or necrosis.
Significantly higher vessel densities in tumors subjected to cyclic hypoxia treat-
ment have previously been observed in intradermal tumors of the same tumor line [6],
where the microvascular density was quantified from histological sections of the tu-
mors. The observed increased vessel density in the tumors exposed to cyclic hypoxia
is most likely due to enhanced angiogenesis induced by hypoxia. This is expected
since, as mentioned before, under hypoxic conditions HIF-1α dimerizes with HIF-1β
resulting in transcription of genes that stimulate angiogenesis, such as VEGF-A,
which has been shown to be over-expressed in tumors subjected to cyclic hypoxia
[6].
Vessel diameter
The mean vessel diameter was calculated averaging all the vessel diameters in the
vascular masks. The results of the quantification of this parameter for the tumors
treated with cyclic hypoxia and the control tumors are shown in Figure 4.13. As can
be observed from the plot, there was no visible trend or difference between the vessel
diameters of the treated and control tumors (p = 0.791). It is interesting though
that the differences in vessel density found between the tumors treated with cyclic
hypoxia and the control tumors does not respond to difference in vessel diameter.
This means that the increase in vessel density is mainly due to the generation of
new vessels with similar diameters and not from large differences in vessel diameters
within the tumors.
Intratumor heterogeneity
The observation of the morphology images of the control tumors gave rise to the
hypothesis that these tumors presented larger spatial variations in vessel density.
Therefore, tumors were divided into 3 concentric regions of interest (ROIs) delimited
by lines drawn at R/3, 2R/3 and R, where R was the radius of the tumor, as
described previously. However, after plotting the vascular density parameters, it was
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observed that the middle ROI (between R/3 and 2R/3) did not vary substantially
from the central ROI (circumscribed by a line drawn at R/3), and that these central
and middle regions did vary greatly from the peripheral ROI. Because of that, it was
decided to present the intratumor heterogeneity results with only the two relevant
concentric ROIs in the tumors: a central ROI (circumscribed by a line drawn at
2R/3) and a peripheral ROI (between the lines drawn at 2R/3 and R). This is
shown in Figure 4.14.
The vascular area fraction (VAF) in treated and control tumors for the central
ROI and peripheral ROI are shown in Figures 4.15 and 4.16, respectively. The
difference in the VAF between the treated and control groups was greater for the
central region (p = 0.032) than the peripheral region (p = 0.225).
The results of this section indicate that the tumors exposed to cyclic hypoxia
developed more homogeneous vascular networks than the control tumors. This could
be because of increased angiogenesis throughout the tumor, due to upregulation of
angiogenic factors. VEGF-A is likely to be responsible of this enhanced angiogenesis,
since it was found to be over-expressed in intradermal tumors subjected to the same
cyclic hypoxia treatment [6].
5.2.2 BST
As shown in Figure 4.18, it was observed that the tumors exposed to cyclic hypoxia
displayed a higher heterogeneity in blood supply times throughout the vascular
network than the control tumors represented in Figure 4.19. These heterogeneities
in BST in the tumors can be better recognized from the BST histograms (shown
in the right panels of Figs. 4.18 and 4.19). A broader BST histogram corresponds
to a tumor with larger variations in BST throughout the vascular network, whereas
a narrow BST histogram correspond to tumors with little variations in the blood
supply. Tumors with little variations in BST can therefore be related a more effective
blood supply, indicating that the whole tumor is supplied of blood in short times.
Conversely, large variations in BST can be related to heterogeneous blood flow with
poor (and perhaps insufficient) blood supply in some regions of the tumor.
The median BST value of each tumor in the treatment and control groups was
plotted in Figure 4.20. The median BST value was chosen instead of the mean value
because it has been observed from previous experiments that the median is a more
robust value, less affected by the noise. In Fig. 4.20 a trend towards higher median
BSTs in the treated tumors than in the control tumors is noticeable. However, this
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apparent difference was not statistically significant (p = 0.148). One possible reason
for this is that the samples of the treated and control tumors were smaller (7 treated
tumors and 8 control tumors) than in the analysis of the morphology (10 tumors in
each group). The reduced number in the samples for the BST analysis was due to
some movies that did not pass the quality control to ensure a reliable determination
of the BSTs.
Nevertheless, the trend towards higher BST in tumors subjected to cyclic
hypoxia could be justified by the fact that hypoxia induced angiogenesis and vascular
remodeling result in new vessels that may be immature and contribute to a less
efficient supply of blood.
5.2.3 Tumor growth
The transfection of GFP into the tumor cells not only made it possible to monitor
a correct implantation of the spheroids, but also facilitated the observations of tumor
growth during these experiments. This can be observed in Figures 4.4 and 4.5, where
a better contrast between the boundaries of the tumor and the rest of the tissue is
evident in the GFP images. For this reason, the area of the tumors at different time
points throughout the experiment was calculated by drawing the tumor perimeter
on the GFP images. Another feature that can be observed in Figures 4.4 and 4.5
is that no vasculature is visible in the tumors on day 1 and 3. This indicates that
the vasculature inside the tumor developed after the third day after implantation of
spheroids.
From the area calculations, Figure 4.6 was obtained; in this figure it is shown
that the tumors subjected to cyclic hypoxia grew slower than the control tumors. It
is interesting that tumors between the two groups had almost identical average sizes
on the third day of the experiment. This could mean that the differences in growth
rate started once the tumors had developed their vascular networks.
Figure 4.7 shows the area of the tumors in the treated and control groups on the
last day of the experiments. Since, as mentioned before, the sizes of the implanted
spheroids did not vary significantly between the two groups (p > 0.05) and that the
size of the tumors in the two groups was equal in average on day 3, the differences
in sizes at the end of the experiment respond to different growth rates between the
group that underwent cyclic hypoxia and the control group. This difference in area
at the end of the experiment was statistically significant (p = 0.045). Differences in
tumor sizes within tumors exposed to cyclic hypoxia and control tumors have also
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been observed in a study by Cairns et al. [4]. In this study they showed that tumors
exposed to cyclic hypoxia grew significantly slower than control tumors, but that in
spite of this, the acute hypoxia treatment enhanced lymph node metastasis.
The reduced growth rate in tumors exposed to cyclic hypoxia occurred in spite
of the increased vessel densities in these tumors. However, the trend towards higher
BST values in the treated tumors might explain this phenomenon since higher BSTs
are related to less efficient supply of blood and, thus, nutrients to the tumor, thereby
limiting its growth rate.
Other experiments involving cyclic hypoxia in tumors have reported increased
metastases in tumors that underwent cyclic hypoxia compared to control tumors
[3, 4, 6, 57]. However, in this experiment it was not possible to study metastatic dis-
semination since metastasis in this tumor line occurs after certain sizes that cannot
be reached when the tumor size is restricted by the window chambers.
5.3 Suggestions for future work
As future work, it would be interesting to perform the same experiments in differ-
ent tumor lines, perhaps with a lower growth rate or a different angiogenic profile,
and compare the results for the different tumor models.
Investigation of the molecular mechanisms that arise as response to cyclic
hypoxia is another interesting possible topic. This window chamber method for the
study of effects of cyclic hypoxia in tumors could also include a group of mice that
received the cyclic hypoxia treatment combined with an antiangiogenic treatment
Since it was observed that the vessel density is increased in tumors exposed
to cyclic hypoxia, it would be relevant to investigate if the cyclic hypoxia treatment
has consequences for the interstitial fluid pressure of the tumors.
Another important suggestion for future work is to acquire the images with a
confocal microscope in order to eliminate the limitations of having three dimensions
projected into two, and study the vascular networks as bidimensional slices, or as
3-dimensional structures reconstructed from the slices.
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It would also be relevant to investigate the metastatic potential of tumors
treated with cyclic hypoxia and if there is a correlation with this and the BST
in tumors. This would however require the use of a different tumor line for the
experiments.
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Chapter 6
Conclusions
Exposure to cyclic hypoxia in A-07-GFP melanoma xenografts resulted in dif-
ferences in growth rate, morphology and function of the vascular networks in the
tumors compared to control tumors. Regarding the differences in the morphology,
tumors treated with cyclic hypoxia displayed increased vascular densities and vas-
cular networks with less intratumor heterogeneities. In relation to the function,
treated tumors had more heterogeneous BST values in the vasculature and showed
a trend towards higher BST median values than the control tumor. The higher
vessel density, lower intratumor heterogeneity and higher median BST values in the
tumors treated with cyclic hypoxia are likely to occur due to hypoxia-induced an-
giogenesis which promotes the development of new vessels and remodeling of the
vascular networks. These mechanisms can increase the vascular densities in the tu-
mors. Moreover, the presence of many new immature vessels can result in a less
efficient circulation in the tumor, and thus, higher BST values. The tumor growth
rate was lower in the tumors treated with cyclic hypoxia. This can be related to
the inefficient blood (and thus, nutrient) supply reflected in the trend towards high
BST values of the treated tumors.
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